

Teleflex Incorporated (TFX)

\$124.82 (Stock Price as of 01/06/2026)

Price Target (6-12 Months): **\$136.00**

Long Term: 6-12 Months	Zacks Recommendation:	Neutral
	(Since: 09/30/25)	
	Prior Recommendation:	Outperform
Short Term: 1-3 Months	Zacks Rank: (1-5)	3-Hold
	Zacks Style Scores:	VGM: B
	Value: A	Growth: C
		Momentum: F

Summary

Teleflex's emphasis on product innovation and broader market reach is driving growth. The recent launch of Barrigel in Japan is encouraging, while the Barrigel product line continues to gain traction in the United States. Also, the Urolift system shows promise backed by favorable clinical data. The Vascular Access benefits from the strength in the Central Access products. The acquisition of BIOTRONIK shows strong growth potential for the company's Interventional segment. We estimate a 7.1% compound annual growth rate (CAGR) in the company's revenues from 2025 to 2027. Expansion efforts into Asia bring long-term growth prospects. Its leveraged balance sheet does not bode well. However, macroeconomic headwinds, unfavorable FX and rising competition remain key concerns.

Data Overview

52 Week High-Low	\$185.94 - \$102.58
20 Day Average Volume (sh)	574,083
Market Cap	\$5.5 B
YTD Price Change	2.3%
Beta	0.93
Dividend / Div Yld	\$1.36 / 1.1%
Industry	Medical - Instruments
Zacks Industry Rank	Top 44% (108 out of 244)


Last EPS Surprise	8.6%
Last Sales Surprise	2.2%
EPS F1 Est- 4 week change	-0.1%
Expected Report Date	02/26/2026
Earnings ESP	0.0%

P/E TTM	8.8
P/E F1	8.9
PEG F1	2.8
P/S TTM	1.7

Price, Consensus & Surprise⁽¹⁾



Sales and EPS Growth Rates (Y/Y %)⁽²⁾



Sales Estimates (millions of \$)⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	822 E	908 E	932 E	977 E	3,638 E
2025	701 A	781 A	913 A	929 E	3,324 E
2024	738 A	750 A	764 A	795 A	3,047 A

EPS Estimates⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	3.05 E	3.73 E	3.88 E	4.24 E	14.90 E
2025	2.91 A	3.73 A	3.67 A	3.71 E	14.02 E
2024	3.21 A	3.42 A	3.49 A	3.89 A	14.01 A

*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, except the estimates, is as of 01/06/2026.

(2) The report's text, the analyst-provided estimates, and the price target are as of 12/15/2025.

Overview

Teleflex is a global provider of medical technology products. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

The company markets and sells its products to hospitals and healthcare providers worldwide through a combination of direct sales force and distributors. Teleflex has approximately 35 manufacturing sites with major manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States.

Following the acquisition of Vascular Solutions in 2017, Teleflex currently has seven reportable segments:

Vascular Access (24% of total revenues in 2024, up 0.8% from 2023): Vascular access business offers products that facilitate a variety of critical care therapies and other applications.

Interventional (19.2%, up 11.6%): This segment is comprised of the North American component of the company's acquired Vascular Solutions business, as well as interventional access and cardiac care businesses.


Anesthesia (12.9%, down 1.5%): This segment is comprised of North American pain management and airway management products and other products.

Surgical (14.8%, down 2.8%): The segment includes a comprehensive range of devices for use in a variety of surgical procedures.

Interventional Urology (10.9%, up 0.9%): This segment provides medical devices primarily used in critical care, surgical applications and cardiac care. It generally serves two end markets — hospitals/ healthcare providers, and home health.

Original Equipment Manufacturer and Development Services (OEM) (11.3%, up 2.7%): This segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.

Other (6.8%, down 30.6%): The segment includes single-use respiratory products and has an operating segment that encompasses the company's Latin American business.



Reasons To Buy:

▲ **Urolift Long-term Prospects:** Since NeoTract's acquisition in 2017 by Teleflex, the company is seeing substantial growth with the UroLift System. UroLift remains a key portfolio in its Interventional Urology unit. The minimally invasive medical device is designed to treat lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). The company enhanced its market penetration by commercializing the UroLift system in Japan and China and introducing the UroLift 2 System and the UroLift ATC Advanced Tissue Control System in the United States.

Teleflex continues to build clinical evidence supporting UroLift as a safe, effective and minimally invasive treatment for BPH. Recently, the company presented several clinical studies reinforcing UroLift's superiority over Rezum and tamsulosin, particularly in terms of early patient satisfaction, rapid symptom relief and sexual function outcomes. Though 2025 saw a temporary headwind from final reimbursement phasing, Teleflex remains focused on growth in Interventional Urology, supported by strong Urolift sales.

▲ **Palette Inclusion, a Significant Value Addition:** Following Palette's business integration, Palette's Barrigel continues to gain traction in the U.S. with strong sequential revenue momentum. Barrigel rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy for prostate cancer. During the third quarter, Barrigel was commercially launched in Japan as a proven safe and effective option to minimize the harmful long-term side effects of prostate radiation therapy. Teleflex's marketing strategy is succeeding, converting urologists and radiation oncologists due to compelling clinical data and Barrigel's ease of use. The company sees several potential long-term opportunities to expand indications for its NASHA product platform. Barrigel delivers precise, ultrasound-guided placement, significantly reducing rectal radiation exposure and Grade 1 plus GI toxicity, while expanding adoption through clinician training in Japan. Favorable trial data supported Barrigel's safety and efficacy in men undergoing hypofractionated post-prostatectomy radiation therapy in the United States and Australia.

▲ **Vascular Access Business Grows:** Teleflex's Vascular Access product line continues to gain market share by offering advanced devices that support critical care therapies and help reduce vascular-related complications. Over the long term, Teleflex remains positioned for steady growth with category leadership in Central Venous Catheters and midlines, anticipated share gains from its novel coated PICC (Peripherally Inserted Central Catheters) portfolio, and new product launches. In 2024, Teleflex launched two devices in Canada the next-generation Arrow VPS Rhythm DLX Device and the NaviCurve Stylet designed to improve PICC insertion procedures and reduce complications. The company also introduced its Pressure Injectable Arrow+ard Blue Plus MSB Procedure Kit across Europe, the Middle East, and Africa, enhancing its market-leading Central Venous Catheter portfolio.

In terms of clinical updates, Teleflex recently announced findings from a new multinational study reporting the efficacy of Arrow Chlorhexidine-Impregnated Central Venous Catheters (CVCs) among ICU patients. Additionally, the use of chlorhexidine-impregnated CVCs was associated with a lower incidence of infection-causing pathogens.

Going by our model, Vascular Access business revenues are expected to grow 4.9% at CER in the fourth quarter of 2025, further growing 3.1% at CER in full-year 2025.

▲ **Strong Momentum in Interventional:** The Interventional product category includes coronary catheters, structural heart support devices, peripheral intervention products, and intra-aortic balloon pumps designed to diagnose and treat coronary and peripheral vascular disease. On July 1, Teleflex completed the acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The acquired Vascular Intervention business revenues were modestly ahead of the company's expectation for the third quarter, and increased 6.9% year over year on a reported basis. Additionally, the segment reported a 76.4% year-over-year increase in revenues. The growth was led by intra-aortic balloon pump catheters, OnControl and complex catheters.

In the previous quarter, the AC3 range Intra-Aortic Balloon Pump received FDA 510(k) clearance. This compact device, designed for patient transport via ground and air ambulances, features a simple interface, proprietary algorithms, a full-sized helium tank, and dual-power options.

Teleflex also reported positive preliminary results from the Ringer Perfusion Balloon Catheter ("PBC") IDE study. The catheter allows continuous blood flow during inflation and supports a recent FDA premarket application for coronary perforation. The Ringer PBC holds FDA breakthrough device designation and is currently approved for balloon dilation with perfusion. In emergency medicine category, QuikClot Control+ received FDA clearance for all grades of internal and external bleeding, expanding its use beyond severe bleeding to general surgery, gynecology, orthopedics, and more, adding about \$150 million to the U.S. addressable market.

Our model forecasts revenue growth of 66.4% at CER in the fourth quarter and 43.1% at CER in 2025 for the Interventional business.

▲ **Business in Asia Holds Long-Term Potential:** Observing strong demand for the company's wide product line in emerging economies, Teleflex is currently focusing on expansion in densely populated geographies like Asia. The company has a solid market base for its Interventional Access and Anesthesia products in this region. In the third quarter, sales within this region were up 25.3% year over year, driven primarily by the Vascular Intervention acquisition. In addition, the company recognized nearly \$9 million stocking order as part of its intra-aortic balloon pump and catheter growth strategy in China. Our model forecasts sales in this region to grow 7.4% at CER in 2025.

Teleflex's innovative product launches across its businesses and expansion efforts in Asian countries should contribute to its growth.

Reasons To Sell:

- ▼ **Highly Leveraged Balance Sheet:** Teleflex exited the third quarter of 2025 with cash and cash equivalents of \$354 million and near-term payables of \$100 million. However, long-term debt was \$2.57 billion, up 42.7% sequentially. For the third quarter of 2025, the debt-to-capital ratio was 41.1%. Meanwhile, times interest earned for the company was negative 2.5% compared with positive 4.1% at the end of the second quarter.
- ▼ **UroLift Under Pressure, Business Spinoff Ahead:** Urolift's recent performance signals a shift in momentum. In the third quarter of 2025, Interventional Urology revenues declined 14.1% year over year, mostly due to continued softness in UroLift performance. The portfolio is under reassessment amid changing utilization trends. The company is currently exploring strategic alternatives, including a potential separation of its businesses (on February 27, Teleflex announced its intention to split the company into two independent, publicly traded companies). The long-term prospects for UroLift may hinge on execution in commercial channels and revitalization of clinical adoption.
- ▼ **Macroeconomic Challenges:** Teleflex is exposed to risks from adverse economic changes in the United States and internationally. The company has been facing substantial cost pressures due to global macroeconomic factors, particularly in materials and services, and closely monitoring the impacts of rising interest rates and the ongoing geopolitical conflicts on its operations. If these tensions further escalate, especially with the imposition of additional economic sanctions, it could potentially have a broader impact on other markets where Teleflex operates, affecting its supply chain, business partners, or customers in those regions. In the third quarter of 2025, Teleflex incurred a 31.9% rise in the cost of goods sold. Our model expects the adjusted cost of goods sold to climb 14.8% in 2025.

Additionally, the healthcare industry has been adversely impacted by shifts in care delivery and service sites, as well as staffing shortages at healthcare facilities, which could potentially affect future demand for the company's products. For more than a year, staffing shortages have remained a bottleneck for UroLift's office-based services. Teleflex reported continued pressure from the UroLift product line in the third quarter of 2025.
- ▼ **Unfavorable Impact of Italian Payback Measure:** In 2015, the Italian government introduced legislation requiring medical device companies supplying goods and services to the Italian national healthcare system, to contribute a portion of their revenues to cover any deficit created by the government budget overspending on medical devices each year. Several companies, including Teleflex, argued that the law was unconstitutional, leading to a pause in payment amounts while the measure was under consideration by the courts.

However, on July 22, 2024, the Italian constitutional court issued an adverse ruling that supported the legislation related to the payback measure on medical device companies. Despite annual accruals since 2015, Teleflex is now adjusting its reserves to reflect the full expected invoice from the Italian government. In 2024, the company recognized a \$13.8 million increase in its reserves to cover the anticipated costs. The adjustment led to a reduction in the revenues from the EMEA region and also restricted the performance of important metrics.
- ▼ **Competitive Landscape Tough:** Teleflex competes with companies, ranging from small start-up enterprises to larger and more established companies that have access to significantly greater financial resources. Furthermore, extensive product research and development and rapid technological advances characterize the market in which it competes. According to Teleflex, it competes primarily based on clinical superiority and innovative features that enhance patient benefit, product reliability, performance, customer and sales support, and cost-effectiveness. Its major competitors include Medtronic and Becton, Dickinson and Company.
- ▼ **Adverse Foreign Exchange Translation Impacts:** Foreign exchange is a major headwind for Teleflex due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the Euro and some other developed market currencies has been constantly hampering the company's performance in the international markets.

Macroeconomic concerns, tough competition and foreign exchange headwinds also weigh on the stock.

Last Earnings Report

TFX Q3 Earnings and Revenues Beat, '25 View Down

Teleflex Incorporated (TFX) posted third-quarter 2025 adjusted earnings per share (EPS) from continuing operations of \$3.67, up 5.2% from the year-ago quarter's figure. The metric topped the Zacks Consensus Estimate by 8.6%.

GAAP loss per share was \$9.24 compared to EPS of \$2.36 in the prior-year period.

TFX's Revenues

Net revenues were up 19.4% year over year to \$913 million. The metric surpassed the Zacks Consensus Estimate by 2%.

Segmental Analysis of TFX's Q3 Revenues

Teleflex has three reportable segments — Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific).

Net revenues in the Americas were \$555.9 million, which increased 7.8% from the year-ago period's level. This compares with our model's projection of \$588.6 million for the quarter.

The EMEA (Europe, the Middle East and Africa) net revenues of \$234.2 million increased 55.9% year over year. Our model projected revenues of \$162.6 million for the quarter.

Revenues from Asia (Asia Pacific) rose 25% to \$122.9 million. Our model's projection was \$142.1 million.

TFX's Q3 Product Revenues in Detail

The Vascular Access segment recorded net revenues of \$191 million, up 5.6% year over year. This compares with our model's projection of \$187.1 million.

The Interventional business registered net revenues of \$266.4 million, up 77.8% year over year. This compares with our model's projection of \$260.3 million.

Within the Anesthesia segment, net revenues increased 0.4% year over year to \$101.4 million. This compares with our model's projection of \$96.9 million.

The Surgical segment recorded net revenues of \$122.9 million, up 10% year over year. Our model's projection was \$114.6 million.

Revenues from the Interventional Urology segment totaled \$71.8 million, down 13.9% year over year. This compares with our model's projection of \$76.9 million.

OEM recorded revenue growth of \$80.4 million, down 2.6% year over year. This compares with our model's projection of \$81 million.

The Other product segment's (consisting of the company's respiratory products not included in the divestiture to Medline, manufacturing service agreement revenues and Urology Care products) net revenues of \$79.1 million reflected a year-over-year increase of 44.4%. This compares with our model's projection of \$76.4 million for the quarter.

TFX's Margin Performance

The gross profit was \$451.6 million, up 5% year over year. The gross margin contracted 681 basis points (bps) to 49.5% due to a 38% rise in the cost of goods sold.

Overall, the adjusted operating profit was \$112.7 million, down 21.9% year over year. The adjusted operating margin contracted 652 bps to 12.3%.

TFX's Liquidity Position

Teleflex exited the third quarter of 2025 with cash and cash equivalents of \$354 million compared with \$253.7 million at the end of the second quarter.

Net cash flow provided by operating activities from continuing operations was \$189 million compared with \$435.6 million in the year-ago period.

Teleflex's Lowered 2025 Guidance

GAAP revenue growth for 2025 is now expected to be in the range of 9.10-9.60% (down from the prior guidance of 9.00-10.00%). The Zacks Consensus Estimate for total revenues is pegged at \$3.32 billion, indicating 8.9% growth year over year.

Teleflex now anticipates adjusted EPS from continuing operations to be in the range of \$14.00-\$14.20 (down from the prior guidance of \$13.90-\$14.30). The Zacks Consensus Estimate for EPS is pegged at \$14.08.

FY Quarter Ending **12/31/2025**

Earnings Reporting Date	Nov 06, 2025
Sales Surprise	2.18%
EPS Surprise	8.58%
Quarterly EPS	3.67
Annual EPS (TTM)	14.20

Recent News

Teleflex to Sell Acute Care, Interventional Urology, and OEM Businesses: Dec. 9, 2025

Teleflex recently entered into a definitive agreement to sell its Acute Care, Interventional Urology and OEM businesses to two buyers. Intersurgical Ltd will buy Acute Care and Interventional Urology and Montagu and Kohlberg will buy OEM, for a combined total of \$2.03 billion in cash, subject to certain closing adjustments.

Valuation

Teleflex shares are down 28.7% in the year-to-date period and down 28.4% in the trailing 12-months. Stocks in the Zacks sub-industry are up 2.2% and Zacks Medical sector is up 6.4% in the year-to-date period. Over the past year, the Zacks sub-industry is down 1.3% and Zacks Medical sector is up 2.4%.

The S&P 500 index is up 18.3% in the year-to-date period and rose 14.3% in the past year.

The stock is currently trading at 8.4X Forward 12-months earnings, which compares to 29.8X for the Zacks sub-industry, 21.0X for the Zacks sector and 23.4X for the S&P 500 index.

Over the past five years, the stock has traded as high as 33.3X and as low as 7.0X, with a 5-year median 16.9X. Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$136 price target reflects 9.0X forward 12-months earnings.


The table below shows summary valuation data for TFX.

Valuation Multiples - TFX					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	8.44	29.80	20.95	23.35
	5-Year High	33.33	40.72	23.60	23.78
	5-Year Low	6.95	25.73	17.86	15.73
	5-Year Median	16.92	32.28	20.66	21.22
P/S F12M	Current	1.55	4.31	2.16	5.27
	5-Year High	7.19	6.36	3.41	5.50
	5-Year Low	1.27	3.83	2.02	3.83
	5-Year Median	3.70	4.77	2.65	5.05
P/B TTM	Current	1.47	4.17	3.96	8.49
	5-Year High	6.14	6.65	6.08	9.17
	5-Year Low	1.14	3.64	3.57	6.60
	5-Year Median	2.66	4.72	4.53	8.05

As of 12/12/2025

Source: Zacks Investment Research

Industry Analysis⁽¹⁾ Zacks Industry Rank: Top 44% (108 out of 244)



Top Peers⁽¹⁾

Company (Ticker)	Rec	Rank
Intuitive Surgical, ... (ISRG)	Outperform	2
AngioDynamics, Inc. (ANGO)	Neutral	3
Boston Scientific Co... (BSX)	Neutral	2
DexCom, Inc. (DXCM)	Neutral	3
Integra LifeSciences... (IART)	Neutral	2
IDEXX Laboratories, ... (IDXX)	Neutral	2
Medtronic PLC (MDT)	Neutral	2
OPKO Health, Inc. (OPK)	Neutral	2

Industry Comparison⁽¹⁾ Industry: Medical - Instruments

	TFX	X Industry	S&P 500	DXCM	IDXX	MDT
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	2	2
VGM Score	B	-	-	B	C	D
Market Cap	5.52 B	152.70 M	40.27 B	27.26 B	56.44 B	128.60 B
# of Analysts	12	2.5	22	9	7	11
Dividend Yield	1.09%	0.00%	1.35%	0.00%	0.00%	2.83%
Value Score	A	-	-	C	D	B
Cash/Price	0.07	0.13	0.04	0.13	0.00	0.07
EV/EBITDA	11.42	-0.84	14.84	27.17	44.54	16.05
PEG Ratio	2.84	2.23	2.06	1.26	3.78	2.64
Price/Book (P/B)	1.44	3.00	3.44	10.00	36.15	2.63
Price/Cash Flow (P/CF)	4.92	17.07	15.60	31.09	56.87	12.94
P/E (F1)	8.90	23.75	18.94	28.33	49.01	17.78
Price/Sales (P/S)	1.73	3.71	3.12	6.04	13.54	3.70
Earnings Yield	12.07%	0.47%	5.28%	3.53%	2.04%	5.62%
Debt/Equity	0.67	0.02	0.57	0.45	0.24	0.57
Cash Flow (\$/share)	25.36	-0.32	8.98	2.25	12.43	7.75
Growth Score	C	-	-	A	B	F
Hist. EPS Growth (3-5 yrs)	4.08%	9.03%	8.24%	29.03%	10.55%	3.56%
Proj. EPS Growth (F1/F0)	0.07%	12.28%	9.18%	25.61%	21.18%	2.73%
Curr. Cash Flow Growth	33.10%	-2.40%	7.00%	9.81%	6.03%	3.92%
Hist. Cash Flow Growth (3-5 yrs)	9.64%	6.29%	7.49%	32.03%	14.56%	2.31%
Current Ratio	2.57	2.26	1.19	1.56	1.18	2.42
Debt/Capital	40.22%	11.33%	38.14%	31.26%	19.36%	36.17%
Net Margin	-10.28%	-14.85%	12.77%	15.96%	24.65%	13.71%
Return on Equity	15.64%	-18.69%	17.03%	30.65%	67.78%	14.86%
Sales/Assets	0.43	0.60	0.53	0.64	1.26	0.38
Proj. Sales Growth (F1/F0)	9.10%	8.56%	5.29%	15.10%	9.90%	7.50%
Momentum Score	F	-	-	F	D	F
Daily Price Chg	0.29%	0.77%	0.62%	3.31%	3.61%	3.03%
1 Week Price Chg	-0.29%	-1.54%	0.70%	-1.52%	-2.69%	-0.49%
4 Week Price Chg	-4.90%	0.89%	1.52%	5.37%	1.11%	0.69%
12 Week Price Chg	2.08%	-2.00%	4.52%	5.56%	10.98%	3.91%
52 Week Price Chg	-30.58%	-13.16%	17.53%	-11.92%	65.43%	25.59%
20 Day Average Volume	574,083	179,218	2,426,458	4,118,561	458,505	5,526,527
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	-0.11%	0.00%	0.00%	-0.66%	0.00%	-0.06%
(F1) EPS Est 12 week change	0.55%	0.00%	0.44%	-3.55%	2.44%	0.48%
(Q1) EPS Est Mthly Chg	-0.10%	0.00%	0.00%	-1.11%	0.00%	-0.20%

Analyst Earnings Model⁽²⁾

Teleflex Incorporated (TFX)

In \$MM, except per share data

	2022A	2023A	2024A	2025E				2026E				2027E		
	FY	FY	FY	1QA	2QA	3QA	4QE	FY	1QE	2QE	3QE	4QE	FY	FY
FY Ends December 31st	Dec-22	Dec-23	Dec-24	31-Mar-25	30-Jun-25	30-Sep-25	31-Dec-25	Dec-25	31-Mar-26	30-Jun-26	30-Sep-26	31-Dec-26	Dec-26	Dec-27
Income Statement														
Total Revenue, Adjusted	\$2,791.0	\$2,974.5	\$3,061.1	\$700.7	\$780.9	\$892.9	\$928.9	\$3,303.4	\$821.6	\$908.4	\$931.5	\$976.6	\$3,638.1	\$3,780.8
Total Revenue	\$2,791.0	\$2,974.5	\$3,047.3	\$700.7	\$780.9	\$913.0	\$928.9	\$3,323.5	\$821.6	\$908.4	\$931.5	\$976.6	\$3,638.1	\$3,780.8
FX	(3.6%)	0.1%	(0.3%)	(1.2%)	1.2%	1.5%	2.2%	1.0%	2.2%	2.2%	2.3%	0.5%	1.8%	0.5%
Constant Currency	2.9%	6.5%	3.1%	(3.8%)	1.0%	15.3%	14.6%	7.0%	15.0%	14.1%	(0.3%)	4.7%	7.7%	3.4%
Adjustment Impact			(0.4%)	0.0%	2.0%	2.6%	0.3%	1.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cost of Goods Sold, Adjusted	\$1,138.7	\$1,204.7	\$1,197.6	\$277.5	\$314.7	\$389.9	\$392.5	\$1,374.5	\$353.2	\$382.0	\$383.7	\$395.6	\$1,514.5	\$1,598.3
Cost of Goods Sold, GAAP	\$1,260.0	\$1,327.6	\$1,344.6	\$311.2	\$349.8	\$461.4	\$431.4	\$1,553.8	\$371.4	\$406.5	\$428.6	\$438.8	\$1,645.2	\$1,710.1
Gross Profit, Adjusted	\$1,652.3	\$1,769.8	\$1,849.7	\$423.2	\$466.2	\$523.2	\$536.5	\$1,949.0	\$468.4	\$526.4	\$547.8	\$581.0	\$2,123.6	\$2,182.5
Gross Profit, GAAP	\$1,531.1	\$1,646.9	\$1,702.7	\$389.4	\$431.1	\$451.6	\$497.5	\$1,769.7	\$450.3	\$501.9	\$502.9	\$537.8	\$1,992.9	\$2,070.7
Selling, General and Administrative, Adjusted	\$784.3	\$859.6	\$871.5	\$215.1	\$218.6	\$253.8	\$263.4	\$960.9	\$256.4	\$275.7	\$282.5	\$290.9	\$1,105.4	\$1,070.0
Selling, General and Administrative, GAAP	\$863.7	\$929.9	\$995.3	\$222.7	\$215.1	\$281.8	\$282.3	\$1,001.8	\$260.1	\$286.6	\$291.3	\$300.4	\$1,138.4	\$1,152.3
Research and Development, Adjusted	\$114.4	\$122.0	\$152.5	\$35.0	\$36.7	\$55.7	\$56.9	\$184.3	\$35.8	\$38.8	\$43.8	\$48.9	\$167.3	\$178.3
Research and Development, GAAP	\$153.8	\$154.4	\$161.7	\$36.4	\$38.5	\$57.2	\$58.0	\$190.1	\$48.3	\$47.6	\$53.5	\$54.0	\$203.3	\$212.3
Pension Settlement Charge	\$0.0	\$45.2	\$132.7	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Goodwill Impairment Charge			\$240.0	\$0.0	\$0.0	\$403.9	\$0.0	\$403.9	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Restructuring and Other Expenses	\$13.8	\$11.2	\$22.0	\$4.8	\$22.2	\$117.6	\$132.4	\$276.9	\$7.1	\$8.3	\$4.0	\$8.9	\$28.2	\$28.8
Total Operating Expenses, Adjusted	\$898.7	\$981.6	\$1,024.0	\$250.1	\$255.4	\$309.5	\$320.2	\$1,135.3	\$292.1	\$314.5	\$326.3	\$339.8	\$1,272.7	\$1,248.4
Total Operating Expenses, GAAP	\$1,031.4	\$1,140.6	\$1,551.7	\$263.9	\$275.8	\$860.5	\$472.6	\$1,872.8	\$315.4	\$342.5	\$348.8	\$363.3	\$1,370.0	\$1,393.3
Depreciation	\$66.5	\$68.1	\$76.9	\$19.4	\$18.2	\$21.2	\$21.9	\$80.6	\$21.0	\$21.8	\$21.9	\$23.0	\$87.6	\$91.4
Amortization of Intangibles	\$164.1	\$174.0	\$197.7	\$47.9	\$47.6	\$56.7	\$54.5	\$206.7	\$53.0	\$54.8	\$56.0	\$58.5	\$222.3	\$233.4
Adjusted EBITDA	\$820.1	\$856.4	\$902.7	\$192.5	\$229.0	\$234.8	\$238.1	\$894.4	\$197.3	\$233.7	\$243.4	\$264.2	\$938.5	\$1,025.5
Operating Income, Adjusted	\$753.6	\$788.2	\$825.7	\$173.1	\$210.8	\$213.6	\$216.2	\$813.8	\$176.3	\$211.9	\$221.5	\$241.2	\$850.9	\$934.2
Operating Income, GAAP	\$499.7	\$506.3	\$151.0	\$125.6	\$155.3	(\$408.9)	\$24.9	(\$103.2)	\$134.8	\$159.4	\$154.2	\$174.5	\$622.9	\$677.3
Interest Expense	\$54.3	\$85.1	\$83.5	\$18.5	\$21.7	\$31.8	\$28.6	\$100.7	\$22.0	\$22.9	\$27.6	\$27.5	\$100.1	\$112.0
Interest Income	\$0.9	\$12.8	\$8.0	\$1.9	\$1.6	\$2.2	\$2.1	\$7.8	\$1.3	\$1.7	\$4.5	\$2.7	\$10.4	\$13.4
Interest Expense (Income), Net	\$53.4	\$72.3	\$75.5	\$16.6	\$20.1	\$29.7	\$26.5	\$92.9	\$20.7	\$21.2	\$23.1	\$24.8	\$89.7	\$98.5
Loss on Extinguishment of Debt	\$0.5	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Pre-Tax Income, Adjusted	\$701.2	\$715.1	\$753.4	\$156.3	\$190.1	\$178.5	\$189.7	\$714.6	\$155.6	\$190.7	\$198.4	\$216.4	\$761.2	\$835.6
Pre-Tax Income, GAAP	\$445.9	\$434.0	\$75.5	\$108.9	\$135.2	(\$438.6)	(\$1.6)	(\$196.0)	\$114.1	\$138.2	\$131.1	\$149.7	\$533.2	\$578.8
Income Tax, Adjusted	\$83.4	\$75.4	\$93.4	\$22.8	\$24.7	\$16.2	\$25.4	\$89.1	\$20.9	\$25.6	\$26.6	\$29.0	\$102.0	\$112.0
Income Tax, GAAP	\$83.0	\$76.4	\$5.3	\$13.8	\$12.7	(\$29.7)	(\$0.2)	(\$3.4)	\$15.3	\$18.5	\$17.6	\$20.1	\$71.4	\$77.6
Tax Rate, Adjusted	11.9%	10.5%	12.4%	14.5%	13.1%	9.1%	13.4%	12.5%	13.4%	13.4%	13.4%	13.4%	13.4%	13.4%
Tax Rate, GAAP	18.6%	17.6%	7.0%	12.7%	9.4%	6.8%	13.4%	1.7%	13.4%	13.4%	13.4%	13.4%	13.4%	13.4%
Net Income from Continuing Operations, Adjusted	\$617.8	\$639.7	\$660.0	\$133.5	\$165.4	\$162.3	\$164.3	\$625.5	\$134.8	\$165.2	\$171.8	\$187.4	\$659.2	\$723.7
Net Income from Continuing Operations, GAAP	\$362.9	\$357.6	\$70.2	\$95.1	\$122.6	(\$408.9)	(\$1.4)	(\$192.6)	\$98.8	\$119.7	\$113.5	\$129.7	\$461.7	\$501.2
Net Income from Discontinuing Operation	\$0.2	(\$1.2)	(\$0.5)	(\$0.1)	(\$0.0)	(\$0.0)	(\$0.0)	(\$0.1)	(\$0.0)	(\$0.0)	(\$0.0)	(\$0.0)	(\$0.1)	(\$0.1)
Net Income, GAAP	\$363.1	\$356.3	\$69.7	\$95.0	\$122.6	(\$408.9)	(\$1.4)	(\$192.7)	\$98.8	\$119.7	\$113.5	\$129.7	\$461.7	\$501.2
Diluted Shares Outstanding	47.3	47.3	47.1	45.9	44.3	44.2	44.2	44.2	44.2	44.2	44.2	44.2	44.2	44.2
Diluted EPS from Continuing Operations, Adjusted	\$13.06	\$13.52	\$14.01	\$2.91	\$3.73	\$3.67	\$3.71	\$14.02	\$3.05	\$3.73	\$3.88	\$4.24	\$14.90	\$16.36
Diluted EPS from Continuing Operations, GAAP	\$7.67	\$7.56	\$1.49	\$2.07	\$2.77	(\$9.24)	(\$0.03)	(\$4.43)	\$2.23	\$2.71	\$2.57	\$2.93	\$10.44	\$11.33
Diluted EPS, GAAP	\$7.68	\$7.53	\$1.48	\$2.07	\$2.77	(\$9.24)	(\$0.03)	(\$4.43)	\$2.23	\$2.71	\$2.57	\$2.93	\$10.44	\$11.33
Dividend per Share	\$1.36	\$1.36	\$1.36	\$0.34	\$0.34	\$0.34	\$0.34	\$1.36	\$0.34	\$0.34	\$0.34	\$0.34	\$1.36	\$1.36

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	C
Momentum Score	F
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.